Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug TUB-030 targets Hard-to-Treat cancers in early trial

NCT ID NCT06657222

Recruiting now Disease control Sponsor: Tubulis GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TUB-030 (an antibody-drug conjugate targeting 5T4 protein)

What this could lead to

If successful, this could lead to a new treatment option for several advanced solid cancers that are hard to treat.

What could go wrong

This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or may have unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma Head and Neck Neoplasms head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CRC HNSCC NSCLC SCLC TNBC, TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arensia Exploratory Medicine

    RECRUITING

    Bucharest, Romania

  • Arensia Exploratory Medicine

    RECRUITING

    Cluj-Napoca, Romania

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Clinica Uni de Navara

    RECRUITING

    Madrid, Spain

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Mount Sinai

    RECRUITING

    New York, New York, 11766, United States

  • NEXT Oncology - Dallas

    RECRUITING

    Irving, Texas, 75039, United States

  • NEXT Oncology - San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • NEXT Oncology Austin

    RECRUITING

    Austin, Texas, 78758, United States

  • Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Princess Margaret

    RECRUITING

    Toronto, Canada

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

  • Washington University

    RECRUITING

    St Louis, Missouri, 63130, United States

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06510, United States